| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Loss before income taxes | -10,806 | -8,291 | ||
| Income tax benefit (expense) | 5 | -3 | ||
| Net loss | -10,811 | -8,288 | ||
| Series a preferred stock conversion inducement | 18,516 | - | ||
| Deemed dividend related to seriesa preferred stock conversion | 11,947 | - | ||
| Undeclared dividends on series a preferred stock | 0 | 714 | ||
| Net loss attributable to common stockholders | -41,274 | -9,002 | ||
| Net loss per common share, basic (in dollars per share) | -0.96 | -0.27 | ||
| Net loss per common share, diluted (in dollars per share) | -0.96 | -0.27 | ||
| Weighted average common shares outstanding, basic (in shares) | 43,057,632 | 32,899,297 | ||
| Weighted average common shares outstanding, diluted (in shares) | 43,057,632 | 32,899,297 | ||
TriSalus Life Sciences, Inc. (TLSIW)
TriSalus Life Sciences, Inc. (TLSIW)